Skip to main content
Triangle logo TriangleGet started

Telisotuzumab Vedotin (NCT06568939)

A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC): a one-minute explainerNCT065689391 min

Telisotuzumab Vedotin trial for Non-Small Cell Lung Cancer (NCT06568939). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for adults with advanced or metastatic nonsquamous lung cancer, without activating EGFR mutations. At least 25% of tumor cells must show strong c-Met staining. Prior docetaxel is excluded.

The idea: telisotuzumab vedotin targets c-Met to deliver a cell-division blocker. Patients are randomized among three intravenous dosing regimens. Researchers compare safety and tumor response; doses are not published in the record.

This phase 2 study plans 150 patients. AbbVie sponsors it, with 39 recruiting US sites. Progression after prior therapy is required; at most one prior cytotoxic chemotherapy line is allowed.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.